secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2026-08-11T21:05:23+00:00
Accession:  0001193125-26-344978
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark reports Q2 net loss $14.4M; ARD-101 clinical hold, HERO/OLE terminated
-------------------------------------------------------------------------------

- Cash $73.9M as of Jun 30, 2026 vs $91.2M at Mar 31; funds operations into late 2027.
- Q2 R&D $10.5M vs $13.1M YoY; G&A $4.6M vs $2.7M; net loss $14.4M both periods.
- FDA full clinical hold on ARD-101 IND in May 2026; HERO and OLE trials terminated June 2026.
- Assessing unblinded HERO and OLE data in Q3 2026 to determine next steps for ARD-101.
- Active FDA discussions to resolve clinical hold; workforce reduction in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/0001193125-26-344978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/ck0001774857-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer